Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt to Equity (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Debt to Equity for 5 consecutive years, with -$1.13 as the latest value for Q2 2022.

  • Quarterly Debt to Equity rose 10.96% to -$1.13 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was -$1.13 through Jun 2022, up 10.96% year-over-year, with the annual reading at -$1.15 for FY2021, 11.18% up from the prior year.
  • Debt to Equity for Q2 2022 was -$1.13 at Theravance Biopharma, down from -$1.12 in the prior quarter.
  • The five-year high for Debt to Equity was -$1.02 in Q4 2019, with the low at -$4.45 in Q4 2018.
  • Average Debt to Equity over 5 years is -$1.62, with a median of -$1.27 recorded in 2021.
  • The sharpest move saw Debt to Equity surged 76.99% in 2019, then decreased 26.13% in 2020.
  • Over 5 years, Debt to Equity stood at -$4.45 in 2018, then soared by 76.99% to -$1.02 in 2019, then dropped by 26.13% to -$1.29 in 2020, then increased by 11.18% to -$1.15 in 2021, then rose by 1.26% to -$1.13 in 2022.
  • According to Business Quant data, Debt to Equity over the past three periods came in at -$1.13, -$1.12, and -$1.15 for Q2 2022, Q1 2022, and Q4 2021 respectively.